{"id":"amg-162-prolia","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Back pain"},{"rate":"10-20%","effect":"Pain in extremity"},{"rate":"10-20%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to RANKL, Prolia inhibits its interaction with its receptor, RANK, on the surface of osteoclasts, thereby reducing bone resorption and increasing bone density. This mechanism of action is particularly relevant in the treatment of osteoporosis and other bone-related disorders.","oneSentence":"AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:36.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoporosis in postmenopausal women"},{"name":"Treatment of bone loss in patients with glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT06588153","phase":"PHASE4","title":"A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-05-24","conditions":"Glucocorticoid-induced Osteoporosis","enrollment":100},{"nctId":"NCT04608630","phase":"PHASE2","title":"Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2021-07-15","conditions":"Critical Illness, Osteoporosis","enrollment":450},{"nctId":"NCT04800367","phase":"PHASE2","title":"Romosozumab/Denosumab Study for Premenopausal IOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2021-03-12","conditions":"Premenopausal Idiopathic Osteoporosis","enrollment":30},{"nctId":"NCT02833610","phase":"PHASE2","title":"A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-08","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT06811363","phase":"","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-28","conditions":"Osteoporosis","enrollment":25},{"nctId":"NCT07406685","phase":"PHASE4","title":"The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-03-17","conditions":"Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Primary Osteoporosis","enrollment":52},{"nctId":"NCT06332014","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-08-06","conditions":"Osteoporosis","enrollment":102},{"nctId":"NCT06118905","phase":"PHASE4","title":"Preserving Geriatric Muscle With an Osteoporosis Medication","status":"RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2024-02-08","conditions":"Osteoporosis","enrollment":155},{"nctId":"NCT05405725","phase":"PHASE3","title":"A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®","status":"COMPLETED","sponsor":"Enzene Biosciences Ltd.","startDate":"2022-07-04","conditions":"Postmenopausal Osteoporosis","enrollment":504},{"nctId":"NCT06374459","phase":"PHASE1, PHASE2","title":"Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-30","conditions":"Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer","enrollment":152},{"nctId":"NCT03839459","phase":"PHASE2","title":"Denosumab for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-04-19","conditions":"Smoldering Multiple Myeloma","enrollment":20},{"nctId":"NCT07063797","phase":"NA","title":"Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":"Type 2 Diabetes, Osteoporosis, Fractures","enrollment":358},{"nctId":"NCT05419050","phase":"PHASE2","title":"Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia","status":"COMPLETED","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2022-10-12","conditions":"Fibrous Dysplasia","enrollment":15},{"nctId":"NCT05666310","phase":"PHASE4","title":"Muscle Impact of Treating Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nami Safai Haeri","startDate":"2023-02-14","conditions":"Sarcopenia, Osteoporosis","enrollment":20},{"nctId":"NCT05866029","phase":"NA","title":"Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-26","conditions":"Osteoporotic Fractures","enrollment":2478},{"nctId":"NCT07329543","phase":"","title":"AGE Burden and Response to Antiresorptive Therapy in Osteoporosis","status":"NOT_YET_RECRUITING","sponsor":"Bursa City Hospital","startDate":"2026-01-15","conditions":"Osteoporosis, Postmenopausal Osteoporosis","enrollment":240},{"nctId":"NCT06767150","phase":"PHASE4","title":"StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-10-02","conditions":"Postmenopausal Osteoporosis","enrollment":200},{"nctId":"NCT07028268","phase":"PHASE2","title":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-06-24","conditions":"For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors","enrollment":210},{"nctId":"NCT02051218","phase":"PHASE3","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2014-07-16","conditions":"Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases","enrollment":1380},{"nctId":"NCT05245669","phase":"PHASE1","title":"Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"Enzene Biosciences Ltd.","startDate":"2022-01-10","conditions":"Healthy Male Subjects","enrollment":207},{"nctId":"NCT06938152","phase":"PHASE4","title":"Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-08","conditions":"Osteoporosis, Osteoporosis Postmenopausal","enrollment":70},{"nctId":"NCT06300229","phase":"PHASE1, PHASE2","title":"NAPO - Novel Approach for Oligospermia","status":"COMPLETED","sponsor":"Martin Blomberg Jensen","startDate":"2024-03-01","conditions":"Infertility, Male","enrollment":42},{"nctId":"NCT07283887","phase":"PHASE4","title":"Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-12-03","conditions":"Osteoporosis","enrollment":90},{"nctId":"NCT07281586","phase":"PHASE4","title":"Step-down Therapy After Long-term Osteoporosis Treatment","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT07271771","phase":"PHASE4","title":"The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2024-05-21","conditions":"Osteoporosis","enrollment":40},{"nctId":"NCT06706414","phase":"PHASE1, PHASE2","title":"NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-03-01","conditions":"Infertility, Male","enrollment":16},{"nctId":"NCT04549207","phase":"PHASE4","title":"Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-10-09","conditions":"Breast Cancer, Castration-resistant Prostate Cancer","enrollment":240},{"nctId":"NCT05884372","phase":"PHASE4","title":"Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)","status":"COMPLETED","sponsor":"Xi'an Honghui Hospital","startDate":"2023-08-24","conditions":"Osteoporosis in Postmenopausal Women","enrollment":100},{"nctId":"NCT05091099","phase":"PHASE4","title":"The Optimal Sequential Therapy After Long Term Denosumab Treatment","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-01-10","conditions":"Osteoporosis","enrollment":44},{"nctId":"NCT03292146","phase":"PHASE3","title":"Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-10-25","conditions":"Bone Density, Bone Loss, Anorexia Nervosa","enrollment":30},{"nctId":"NCT04087096","phase":"PHASE4","title":"Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-08-24","conditions":"Bariatric Surgery Candidate, Bone Loss","enrollment":36},{"nctId":"NCT04067726","phase":"PHASE2","title":"RANKL Inhibition and Mammographic Breast Density","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-08-27","conditions":"Dense Breasts","enrollment":210},{"nctId":"NCT05655013","phase":"PHASE4","title":"Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2023-05-10","conditions":"Osteoporosis, Postmenopausal","enrollment":200},{"nctId":"NCT04586660","phase":"PHASE4","title":"Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-08-17","conditions":"Giant Cell Tumor of Bone","enrollment":36},{"nctId":"NCT05010590","phase":"PHASE4","title":"Anabolic Therapy in Postmenopausal Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-24","conditions":"Postmenopausal Osteoporosis","enrollment":50},{"nctId":"NCT05101018","phase":"PHASE4","title":"Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2021-11-01","conditions":"Osteoporosis, Spinal Cord Injuries","enrollment":40},{"nctId":"NCT05345691","phase":"PHASE3","title":"Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-05-24","conditions":"Postmenopausal Women With Osteoporosis","enrollment":479},{"nctId":"NCT05630768","phase":"PHASE4","title":"Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-01-03","conditions":"Postmenopausal Osteoporosis","enrollment":149},{"nctId":"NCT05590949","phase":"","title":"Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-18","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT06310824","phase":"PHASE1","title":"Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®","status":"COMPLETED","sponsor":"Xentria, Inc.","startDate":"2024-06-05","conditions":"Healthy Participants","enrollment":225},{"nctId":"NCT06524960","phase":"PHASE1, PHASE2","title":"Denosumab for Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-09-03","conditions":"Type 1 Diabetes","enrollment":45},{"nctId":"NCT06513624","phase":"PHASE1","title":"ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2024-12-09","conditions":"With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer","enrollment":16},{"nctId":"NCT07085520","phase":"PHASE1","title":"A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-07-31","conditions":"Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoporosis","enrollment":12},{"nctId":"NCT05493761","phase":"PHASE4","title":"Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-12-23","conditions":"Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal","enrollment":72},{"nctId":"NCT07062978","phase":"PHASE3","title":"A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-27","conditions":"Postmenopausal Women With Osteoporosis at High Risk of Fracture","enrollment":278},{"nctId":"NCT07056478","phase":"PHASE3","title":"RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","status":"NOT_YET_RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2026-01-01","conditions":"Sarcopenia in Elderly","enrollment":130},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":"Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":20},{"nctId":"NCT07034391","phase":"PHASE2","title":"A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status","status":"RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-12","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05096195","phase":"PHASE4","title":"PRevEnting FracturEs in REnal Disease - 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western University, Canada","startDate":"2022-06-11","conditions":"Kidney Diseases, Dialysis; Complications, Fragility Fracture","enrollment":60},{"nctId":"NCT05395091","phase":"PHASE3","title":"Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-08-23","conditions":"Osteoporosis, Postmenopausal","enrollment":532},{"nctId":"NCT05091086","phase":"PHASE4","title":"The Optimal Long Term Treatment Strategy of Anti-resorptive Medications","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-11-20","conditions":"Osteoporosis, Bone Mineral Density","enrollment":60},{"nctId":"NCT03958565","phase":"","title":"Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":100},{"nctId":"NCT05876949","phase":"PHASE1","title":"AVT03 With Xgeva in Healthy Male Subjects","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2023-07-21","conditions":"This is a Phase I Study Conducted in Healthy Volunteers","enrollment":208},{"nctId":"NCT06504966","phase":"PHASE3","title":"Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®","status":"WITHDRAWN","sponsor":"Xentria, Inc.","startDate":"2025-10","conditions":"Osteoporosis","enrollment":""},{"nctId":"NCT04467983","phase":"PHASE4","title":"Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2021-02-01","conditions":"Osteoporosis, Postmenopausal","enrollment":70},{"nctId":"NCT06164795","phase":"","title":"Sequential Therapies After Osteoanabolic Treatment","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-25","conditions":"Osteoporosis, Postmenopausal","enrollment":150},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT04907539","phase":"PHASE2","title":"A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-11-08","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT03921060","phase":"PHASE4","title":"Markers of Osteoporosis in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-09-02","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT06357741","phase":"","title":"Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-08-01","conditions":"Knee Osteoarthritis","enrollment":30},{"nctId":"NCT04711109","phase":"PHASE3","title":"Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-02-14","conditions":"BRCA1 Mutation, Breast Cancer, Breast Diseases","enrollment":300},{"nctId":"NCT04232657","phase":"PHASE2","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-03-01","conditions":"Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI","enrollment":36},{"nctId":"NCT05338086","phase":"PHASE3","title":"A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2022-03-16","conditions":"Postmenopausal Women With Osteoporosis","enrollment":558},{"nctId":"NCT04907851","phase":"PHASE2","title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-12-10","conditions":"Advanced Solid Tumours","enrollment":45},{"nctId":"NCT06728462","phase":"NA","title":"A Study of Amorphous Calcium Carbonate in Postmenopausal Women","status":"RECRUITING","sponsor":"Universal Integrated Corp.","startDate":"2025-03-04","conditions":"Calcium, Osteoporosis, Bone Mineral Density","enrollment":205},{"nctId":"NCT05361408","phase":"PHASE4","title":"A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2022-02-11","conditions":"Osteoporosis","enrollment":114},{"nctId":"NCT04934072","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2021-06-16","conditions":"Postmenopausal Osteoporosis","enrollment":553},{"nctId":"NCT04591275","phase":"PHASE3","title":"Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-03-31","conditions":"Postmenopausal Osteoporosis","enrollment":278},{"nctId":"NCT03669523","phase":"PHASE2","title":"Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2018-11-06","conditions":"Carcinoma, Non-Small-Cell Lung, Bone Metastases","enrollment":82},{"nctId":"NCT03792763","phase":"PHASE2","title":"Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-09-30","conditions":"Multiple Myeloma","enrollment":8},{"nctId":"NCT04664959","phase":"PHASE3","title":"A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2020-11-26","conditions":"Postmenopausal Osteoporosis","enrollment":457},{"nctId":"NCT06804590","phase":"PHASE3","title":"A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2024-11-16","conditions":"Postmenopausal Women Osteoporosis","enrollment":278},{"nctId":"NCT05966064","phase":"PHASE4","title":"DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)","status":"RECRUITING","sponsor":"Natasha Appelman-Dijkstra","startDate":"2023-06-13","conditions":"Fibrous Dysplasia, McCune Albright Syndrome","enrollment":82},{"nctId":"NCT04534582","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2020-11-03","conditions":"Healthy Male Volunteers","enrollment":252},{"nctId":"NCT03270020","phase":"PHASE2","title":"Denosumab for the Treatment of Adult LCH","status":"COMPLETED","sponsor":"Hellenic Society for the Study of Bone Metabolism","startDate":"2017-09-07","conditions":"Langerhans Cell Histiocytosis","enrollment":10},{"nctId":"NCT05299073","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2022-03-01","conditions":"Healthy Volunteers","enrollment":257},{"nctId":"NCT06749886","phase":"PHASE2","title":"An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-11-19","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT06720350","phase":"PHASE4","title":"Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","startDate":"2025-01-15","conditions":"Osteoporosis in Post-menopausal Women","enrollment":60},{"nctId":"NCT04403698","phase":"PHASE2","title":"The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-11-13","conditions":"Erosive Osteoarthritis","enrollment":30},{"nctId":"NCT04177940","phase":"PHASE4","title":"Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-17","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT04338529","phase":"","title":"Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation","status":"COMPLETED","sponsor":"251 Hellenic Air Force & VA General Hospital","startDate":"2020-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":92},{"nctId":"NCT06472050","phase":"PHASE4","title":"Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-08-20","conditions":"Osteoporosis, Glucocorticoids Toxicity","enrollment":63},{"nctId":"NCT02150850","phase":"","title":"Quebec Registry for Atypical Femur Fractures","status":"RECRUITING","sponsor":"McGill University","startDate":"2012-04","conditions":"Atypical Femur Fracture","enrollment":150},{"nctId":"NCT05212337","phase":"PHASE2","title":"FITMI - First In Treating Male Infertility","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2022-01-01","conditions":"Infertility, Male","enrollment":180},{"nctId":"NCT06361355","phase":"PHASE1","title":"Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2023-11-02","conditions":"Healthy Volunteers","enrollment":128},{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT05087030","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2021-09-21","conditions":"Postmenopausal Osteoporosis","enrollment":473},{"nctId":"NCT06643780","phase":"PHASE4","title":"RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis","status":"RECRUITING","sponsor":"Prince of Wales Hospital, Shatin, Hong Kong","startDate":"2024-04-09","conditions":"Sarcopenia in Elderly","enrollment":120},{"nctId":"NCT03629717","phase":"EARLY_PHASE1","title":"RANKL Inhibition and Breast Tissue Biomarkers","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-06-01","conditions":"Breast Cancer Prevention, Mammographic Density","enrollment":10},{"nctId":"NCT03869762","phase":"PHASE2","title":"Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-01-09","conditions":"Castration-resistant Prostate Cancer, Metastatic Cancer, Bone Metastases","enrollment":7},{"nctId":"NCT02771860","phase":"PHASE2","title":"RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-03","conditions":"Hand Osteoarthritis","enrollment":100},{"nctId":"NCT05352516","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2022-06-17","conditions":"Postmenopausal","enrollment":514},{"nctId":"NCT02129699","phase":"PHASE3","title":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-01-06","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":595},{"nctId":"NCT02753283","phase":"PHASE4","title":"Preventing Osteoporosis Using Denosumab","status":"COMPLETED","sponsor":"Susan L. Greenspan","startDate":"2016-06","conditions":"Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures","enrollment":201},{"nctId":"NCT04091243","phase":"PHASE4","title":"Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2021-01-15","conditions":"Glucocorticoid-induced Osteoporosis","enrollment":70},{"nctId":"NCT01575834","phase":"PHASE3","title":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-15","conditions":"Postmenopausal Osteoporosis","enrollment":7180},{"nctId":"NCT02613416","phase":"PHASE2","title":"Denosumab and MRI Breast Imaging","status":"COMPLETED","sponsor":"Alison Stopeck","startDate":"2015-11","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT04741906","phase":"","title":"Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication","status":"RECRUITING","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2017-08-01","conditions":"Missing Teeth, Implants, Cancer","enrollment":225},{"nctId":"NCT06154707","phase":"PHASE3","title":"Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-02-01","conditions":"Sarcopenia, Osteoporosis, Denosumab","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["denosumab"],"phase":"phase_2","status":"active","brandName":"AMG 162 - Prolia","genericName":"AMG 162 - Prolia","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption. Used for Treatment of osteoporosis in postmenopausal women, Treatment of bone loss in patients with glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}